Analyst Price Targets — HIMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 24, 2026 3:22 pm | — | Truist Financial | $32.00 | $31.25 | TheFly | Hims & Hers price target raised to $32 from $27 at Truist |
| August 20, 2026 1:15 pm | Glen Santangelo | Barclays | $35.00 | $32.83 | StreetInsider | Hims and Hers (HIMS) PT Lowered to $35 at Barclays |
| August 11, 2026 12:41 pm | George Hill | Deutsche Bank | $26.00 | $31.23 | TheFly | Hims & Hers price target raised to $26 from $25 at Deutsche Bank |
| August 11, 2026 11:10 am | Ryan MacDonald | Needham | $42.00 | $31.77 | StreetInsider | Hims and Hers (HIMS) PT Raised to $42 at Needham |
| August 11, 2026 11:08 am | — | Morgan Stanley | $28.00 | $31.77 | TheFly | Hims & Hers price target raised to $28 from $21 at Morgan Stanley |
| July 9, 2026 9:12 am | — | UBS | $37.00 | $36.07 | StreetInsider | Hims and Hers (HIMS) PT Raised to $37 at BofA Securities |
| July 1, 2026 10:44 am | — | Canaccord Genuity | $40.00 | $34.67 | TheFly | Hims & Hers price target raised to $40 from $32 at Canaccord |
| June 17, 2026 6:53 pm | — | Barclays | $39.00 | $31.89 | TheFly | Hims & Hers price target raised to $39 from $29 at Barclays |
| June 2, 2026 12:19 pm | Michael Cherny | Leerink Partners | $25.00 | $27.64 | StreetInsider | Leerink Reiterates Market Perform Rating on Hims and Hers (HIMS) |
| May 26, 2026 9:25 am | — | UBS | $25.00 | $23.75 | StreetInsider | Hims and Hers (HIMS) PT Lowered to $25 at BofA Securities |
Latest News for HIMS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the…
HIMS INVESTOR ALERT: Hims and Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims and Hers Class Action Lawsuit
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"), have until November 2, 2026 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit.
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HIMS.
U.S. House Trading
No House trades found for HIMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.